XULTOPHY

Xultophy 100/3.6 is a combination medication that contains liraglutide, a long-acting agonist of the glucagon-like peptide-1 receptor, and insulin degludec, a long-acting basal insulin.

Quantity: 15 units
Per unit price: $87.59
Total price: $1,313.87

Xultophy® (IDegLira) combines basal insulin degludec and GLP-1 receptor agonist liraglutide in a fixed ratio.

Xultophy is a medication that combines insulin degludec and liraglutide. It is used to treat type 2 diabetes in adults and helps improve glycemic control when used alongside a healthy diet and exercise. Xultophy is administered through subcutaneous injections.

Xultophy 100/3.6, a generic version of Xultophy 100/3.6, contains two active ingredients: insulin degludec and liraglutide. These two drugs are also sold separately under different brand names. Insulin degludec is marketed as Tresiba, while liraglutide is sold as Victoza.

Ozempic is potentially more effective than Victoza in reducing hemoglobin A1C levels, indicating better control of average blood glucose levels over a 3-month period. Additionally, Ozempic may lead to greater weight loss. However, it is important to note that Victoza is approved for use in children aged 10 and above, while Ozempic is only approved for adults.

When transitioning from Victoza to Ozempic, it is recommended to take your initial Ozempic dose the day following your final Victoza dose. Your doctor will determine the appropriate dosage of Ozempic for you when switching medications. They may begin with a lower dose and gradually increase it as needed.

Trulicity and Victoza are both utilized, in conjunction with diet and exercise, to decrease blood sugar levels in adults with type 2 diabetes, with a study determining that they are equally effective in treating this condition.

Ozempic, Trulicity, and Victoza are all part of the same drug class and function similarly to reduce blood sugar levels. Additionally, all three medications are administered through subcutaneous injections. However, there is a difference in dosing frequency, as Ozempic and Trulicity are given once a week, whereas Victoza injections are administered once daily.

Available Dosage Forms:
– Subcutaneous solution
– Oral solution
– Oral tablet
– Oral tablet, extended release

Brand Names:
– Victoza (liraglutide)
– Saxenda (liraglutide)
– Glumetza (metformin)
– Ozempic (semaglutide)
– Rybelsus (semaglutide)
– Wegovy (semaglutide)

You can pay $1,334 at both Walgreens and CVS Pharmacy with a NowPatient Rx Advantage Card discount. This is a 7% discount off the retail price of $1,430.

Victoza and Ozempic are both brand-name drugs and do not have generic versions available. Typically, brand-name medications tend to be more costly compared to generics.

In summary, Xultophy is more effective than Lantus in reducing A1c levels, weight, and nocturnal hypoglycemia, with fewer significant side effects. Over five times as many patients on Xultophy achieved an A1c below 7% without experiencing hypoglycemia or weight gain compared to those on Lantus.

Semglee and Rezvoglar are both biosimilars to Lantus, while Basaglar is a follow-on biologic version of Lantus. The reason for this distinction is that Basaglar was approved prior to the implementation of the biosimilar approval pathway for insulin.

Similar to other insulin products, Xultophy 100/3.6, which contains insulin degludec as one of its active drugs, has been shown to cause weight gain. Studies of the drug have found that, on average, people using Xultophy 100/3.6 gained about 4.4 pounds.

Xultophy (insulin degludec / liraglutide) is a combination injection that effectively treats type 2 diabetes. Its once-daily administration makes it a convenient option. However, it is not typically recommended as a first-line treatment due to the potential risk of thyroid cancer.

Xultophy is a pen injection that combines insulin degludec and liraglutide. Insulin degludec is a long-acting insulin that begins working a few hours after injection and provides consistent coverage for 24 hours.

Insulin glargine, found in Lantus, Basaglar, and Toujeo, has a duration of at least 24 hours. Among these, Toujeo has the longest duration, lasting up to 36 hours. Additionally, there are approved biosimilars of Lantus, such as Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr).

Please use Xultophy® 100/3.6 at the same time every day, regardless of whether you have eaten or not. It is important not to exceed 50 units of Xultophy® 100/3.6 per day. Before each injection, double-check the Pen label to ensure that you are using the correct medication.

Insulin Glargine U-100 is an unbranded biologic that is indistinguishable from Lantus.

Trulicity and Lantus are distinct diabetes medications with different mechanisms of action. Trulicity functions as a human GLP-1 receptor agonist, while Lantus is a synthetic version of a naturally occurring hormone. Both medications share common side effects such as weakness, lack of energy, and the potential for low blood sugar (hypoglycemia).

Lantus® (insulin glargine) possesses beneficial medical characteristics. In comparison to Novolin® 30R, Lantus® exhibits a slower absorption rate, an extended duration of effectiveness, and does not have a peak plasma concentration. These attributes align with the natural pattern of human insulin secretion.

Findings: When compared to glargine, degludec shows similar HbA1c control but significantly lower rates of nocturnal hypoglycemia. In addition, in patients with type 1 diabetes or those who are insulin-naïve with type 2 diabetes, degludec also leads to greater reductions in fasting plasma glucose and requires lower total doses of insulin compared to glargine.

No, Xultophy 100/3.6 is not indicated for weight loss. Its primary purpose is to manage blood sugar levels in adults with type 2 diabetes. In fact, some individuals may experience slight weight gain while using Xultophy.

Injectable drugs such as dulaglutide (Trulicity), liraglutide (Victoza), and semaglutide (Ozempic) are used for the treatment of diabetes and obesity. Additionally, semaglutide is available in pill form called Rybelsus. Liraglutide and semaglutide are also approved for weight loss and are marketed as Saxenda and Wegovy, respectively.

Xultophy should be administered once daily, ideally at a consistent time. The dosage is tailored to each patient, and their blood glucose levels should be monitored regularly to determine the most effective dose. For further guidance on using Xultophy, refer to the package insert or consult with your physician or pharmacist.

According to research, semaglutide 2.4 mg (Wegovy) has been found to facilitate weight loss of up to 20% within a year. Comparatively, liraglutide (brand name Saxenda) and dulaglutide (brand name Trulicity) are less effective than semaglutide and are associated with a higher occurrence of adverse side effects.

Insulin degludec, an ultra long-acting insulin, starts to take effect a few hours following injection and remains active for up to 42 hours. It is gradually and consistently released into the bloodstream after being administered.

To prevent weight gain, it is important to count calories and consume fewer calories through food and drink. Skipping meals is not an effective way to cut calories. Staying physically active is also crucial. If you have diabetes, consult with your healthcare provider about other medication options. It is important to take insulin only as directed.

Please integrate Xultophy® 100/3.6 into your ePrescribing system. The Xultophy® 100/3.6 Pen allows for doses ranging from 10 to 50 units in a single injection, with dose increments of 1 unit (1 unit = 1 unit of insulin degludec and 0.036 mg liraglutide).

Xultophy® 100/3.6 is a medication that needs to be injected once daily, preferably at the same time every day.

Each prefilled disposable pen contains 300 units of Xultophy 100/3.6, which is equivalent to 300 units of insulin degludec and 10.8 mg of liraglutide.

Soliqua and Xultophy have not been directly compared, but both are effective treatments for type 2 diabetes. Both reduce HbA1c and fasting blood glucose levels.